Get the Stockscreener App
85.90
2.96%
2.50
After Hours:
85.90
Edwards Lifesciences Corp stock is traded at $85.90, with a volume of 2.85M.
It is up +2.96% in the last 24 hours and up +1.90% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$83.40
Open:
$83.85
24h Volume:
2.85M
Relative Volume:
0.73
Market Cap:
$49.84B
Revenue:
$6.07B
Net Income/Loss:
$1.06B
P/E Ratio:
46.36
EPS:
1.8527
Net Cash Flow:
$799.60M
1W Performance:
+8.81%
1M Performance:
+1.90%
6M Performance:
+5.66%
1Y Performance:
+19.33%
1-Day Range:
$83.67
$85.92
1-Week Range:
$78.00
$85.87
52-Week Range:
$65.94
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
85.89 | 48.40B | 6.07B | 1.06B | 799.60M | 1.8527 |
|
ABT
Abbott Laboratories
|
116.17 | 199.55B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
386.07 | 146.96B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
97.00 | 123.91B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
75.67 | 109.04B | 20.08B | 2.89B | 3.66B | 1.9391 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-03-25 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insigh - GuruFocus
Edwards Lifesciences Hits Day High with Strong 3.33% Intraday Surge - Markets Mojo
Edwards Lifesciences Opens with 3.2% Gain, Outpacing S&P 500's 0.69% Increase - Markets Mojo
Edwards Lifesciences Stock Climbs 1.21% on Stronger Revenue, $0.35 Billion Trading Volume Ranks 387th for the Day - Bitget
Zacks Industry Outlook Highlights Intuitive Surgical, Edwards Lifesciences and Electromed - Yahoo Finance
NEW SURVEY BY EDWARDS LIFESCIENCES UNCOVERS JUST HOW MUCH AMERICANS KNOW ABOUT THEIR HEART HEALTH - Yahoo Finance
Daiwa Securities Adjusts Price Target on Edwards Lifesciences to $98 From $99, Maintains Buy Rating - marketscreener.com
Here is Why Edwards Lifesciences Corporation (EW) Looks Attractive - Insider Monkey
Edwards Lifesciences Corp (EW)'s Winning Formula: Financial Metr - GuruFocus
Equitable Trust Co. Sells 15,075 Shares of Edwards Lifesciences Corporation $EW - Defense World
Cardiac Valve Market 20262035 Major Key Players: Edwards - openPR.com
Edwards Lifesciences Stock at $78: Here’s the Analysts’ Bull Case Scenario - TIKR.com
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing - The Motley Fool
Edwards Lifesciences to Present at the Barclays and Leerink Partners Global Healthcare Conferences - marketscreener.com
First National Bank of Omaha Purchases New Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Alberta Investment Management Corp Buys Shares of 68,300 Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences advances smart surgery monitoring with completed SMART TRENDS study - MSN
Edwards Lifesciences Corporation $EW Holdings Raised by Vanguard Group Inc. - MarketBeat
Edwards Lifesciences (NYSE:EW) Trading Up 5.6%Here's Why - MarketBeat
Edwards Lifesciences Corp. Drops ‘Anti-Copycatting’ Policy Amid EU Probe - USA Herald
Edwards Sued In Chancery Over $300M Heart Valve Earn-Out - Law360
Edwards Lifesciences (EW) Rises as EU Antitrust Probe Ends - GuruFocus
Edwards Lifesciences (EW) Experiences Significant Price Surge - GuruFocus
European Commission ends Edwards antitrust probe after company withdraws anti-copycat policy - MassDevice
Edwards Lifesciences Corporation $EW Shares Sold by PNC Financial Services Group Inc. - MarketBeat
Edwards Lifesciences (NYSE:EW) Shows Institutional Concentration Trends Within The S&P 500 Today - Kalkine Media
Edwards Lifesciences Corporation (NYSE:EW) is a favorite amongst institutional investors who own 88% - Yahoo Finance
Tobam Has $5.22 Million Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
EU Closes Antitrust Investigation Against US' Edwards Lifesciences - marketscreener.com
Edwards Lifesciences scraps anti-copycat policy, EU drops antitrust investigation - Reuters
Eu antitrust regulators close investigation into edwards lifesciences after company withdraws anti-copycat policy - marketscreener.com
Achy Breaky Heart: The FTC Blocks Edwards-JenaValve Aortic Device Deal - marketscreener.com
What’s the outlook for Edwards Lifesciences Corporation’s sectorQuarterly Growth Report & Fast Moving Stock Watchlists - mfd.ru
Edwards Lifesciences Corporation (EW) Draws Positive Analyst View After Q4 Update - Finviz
Envestnet Asset Management Inc. Cuts Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences completes key study on SAPIEN XT THV - MSN
Is Edwards Lifesciences Corporation stock a smart retirement pickPortfolio Value Summary & Free Accurate Trade Setup Notifications - mfd.ru
Edwards Lifesciences to Present at Citi’s 2026 Unplugged Medtech and Life Sciences Access Day - The AI Journal
Rhumbline Advisers Acquires 15,792 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
How Investors Are Reacting To Edwards Lifesciences (EW) 2026 Guidance After Profit Squeeze In 2025 - Yahoo Finance
Halper Sadeh LLC Encourages Edwards Lifesciences - GlobeNewswire
Edwards Lifesciences Corporation $EW Shares Bought by Oppenheimer Asset Management Inc. - MarketBeat
Wells Fargo Raises Price Target for Edwards Lifesciences (EW) | - GuruFocus
Edwards Lifesciences Leans Into Growth After Strong Quarter - TipRanks
Edwards Lifesciences (EW): Truist Securities Maintains Hold Rati - GuruFocus
Edwards Lifesciences (EW) Analyst Ratings Update: Price Target L - GuruFocus
Edwards Lifesciences (NYSE:EW) Advances Structural Heart Solutions - Kalkine Media
Edwards Lifesciences Corp (NYSE:EW) Issues Upbeat Guidance - FXDailyReport.Com
Rothschild & Co Redburn Adjusts Edwards Lifesciences PT to $94 From $93, Maintains Buy Rating - marketscreener.com
Edwards Lifesciences 2026 Growth Targets Achievable, RBC Says - marketscreener.com
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):